{
  "ticker": "AYA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958544",
  "id": "02958544",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250616",
  "time": "0848",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krxt0j8lx0cn.pdf",
  "summary": "- **FDA 510(k) submission** filed for Salix\u00ae Coronary Plaque module (AI-powered plaque detection).  \n- **Expected FDA clearance**: Q3 2025.  \n- **Reimbursement**: Qualifies for U.S. Category 1 CPT code at **US$950 per assessment** (effective January 2026).  \n- **Commercial partnerships**: Agreements with 3 U.S. hospital systems (15 hospitals total); initial rollout of Salix\u00ae Coronary Anatomy underway.  \n- **SAPPHIRE study** to validate Plaque Dispersion Score, potentially expanding commercial sites post-clearance.  \n\n*No capital raising, financials, or trading halt information identified.*",
  "usage": {
    "prompt_tokens": 2005,
    "completion_tokens": 144,
    "total_tokens": 2149,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T22:53:38.186800"
}